Everolimus-based combination for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): biological rationale and critical review of published data
出版年份 2015 全文链接
标题
Everolimus-based combination for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): biological rationale and critical review of published data
作者
关键词
Everolimus, Systemic treatment, Neuroendocrine neoplasms
出版物
TUMOR BIOLOGY
Volume 36, Issue 2, Pages 467-478
出版商
Springer Nature
发表日期
2015-01-17
DOI
10.1007/s13277-015-3064-4
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Targeting vascular endothelial growth factor (VEGF) pathway in gastric cancer: Preclinical and clinical aspects
- (2015) Omar Abdel-Rahman CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: An ITMO group study
- (2014) Emilio Bajetta et al. CANCER
- RAF signaling in neuroendocrine neoplasms: From bench to bedside
- (2014) Nicola Fazio et al. CANCER TREATMENT REVIEWS
- Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours
- (2014) V. Ramundo et al. CLINICAL ENDOCRINOLOGY
- Risk of mucocutaneous toxicities in patients with solid tumors treated with everolimus; a systematic review and meta-analysis
- (2014) Omar Abdel-Rahman et al. Expert Review of Anticancer Therapy
- Bevacizumab-based combination therapy for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a systematic review of the literature
- (2014) Omar Abdel-Rahman et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Metronomics: towards personalized chemotherapy?
- (2014) Nicolas André et al. Nature Reviews Clinical Oncology
- Vascular endothelial growth factor (VEGF) pathway and neuroendocrine neoplasms (NENs): prognostic and therapeutic considerations
- (2014) Omar Abdel-Rahman TUMOR BIOLOGY
- Biotherapies for GEP-NETs
- (2013) Kjell Öberg BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY
- An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: correlation with tumour phenotype and survival outcomes
- (2013) D J Pinato et al. BRITISH JOURNAL OF CANCER
- A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor
- (2013) Jennifer A. Chan et al. CANCER
- Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors
- (2013) Jennifer A. Chan et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A systematic review of non-surgical treatments for pancreatic neuroendocrine tumours
- (2013) Juan W. Valle et al. CANCER TREATMENT REVIEWS
- Targeted therapy with kinase inhibitors in aggressive endocrine tumors
- (2013) Vincenzo Marotta et al. EXPERT OPINION ON PHARMACOTHERAPY
- Gastroenteropancreatic Neuroendocrine Tumors: Update on Therapeutics
- (2012) Alex Ganetsky et al. ANNALS OF PHARMACOTHERAPY
- Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors
- (2012) Jennifer A Chan et al. ENDOCRINE-RELATED CANCER
- TNM Staging of Neoplasms of the Endocrine Pancreas: Results From a Large International Cohort Study
- (2012) G. Rindi et al. JNCI-Journal of the National Cancer Institute
- A unifying model for mTORC1-mediated regulation of mRNA translation
- (2012) Carson C. Thoreen et al. NATURE
- Prognostic significance of AKT/mTOR signaling in advanced neuroendocrine tumors treated with somatostatin analogs
- (2012) Isabel Fernandes et al. OncoTargets and Therapy
- Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
- (2011) Marianne E Pavel et al. LANCET
- Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
- (2011) Eric Raymond et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Angiogenic markers endoglin and vascular endothelial growth factor in gastroenteropancreatic neuroendocrine tumors
- (2011) Patricia Kuiper WORLD JOURNAL OF GASTROENTEROLOGY
- First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas
- (2010) Jonathan R. Strosberg et al. CANCER
- Compensatory activation of Akt in response to mTOR and Raf inhibitors – A rationale for dual-targeted therapy approaches in neuroendocrine tumor disease
- (2010) Kathrin Zitzmann et al. CANCER LETTERS
- VEGF Secretion by Neuroendocrine Tumor Cells Is Inhibited by Octreotide and by Inhibitors of the PI3K/AKT/mTOR Pathway
- (2010) Karine Villaume et al. NEUROENDOCRINOLOGY
- Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors
- (2009) Takashi Shida et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors
- (2009) Dik J Kwekkeboom et al. ENDOCRINE-RELATED CANCER
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
- (2009) Anja Rinke et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors
- (2008) Ulrich‐Frank Pape et al. CANCER
- Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study
- (2008) James C. Yao et al. JOURNAL OF CLINICAL ONCOLOGY
- Angiogenesis and Tumor Progression in Neuroendocrine Digestive Tumors
- (2008) Gilles Poncet et al. JOURNAL OF SURGICAL RESEARCH
- Gastroenteropancreatic neuroendocrine tumours
- (2008) Irvin M Modlin et al. LANCET ONCOLOGY
- Octreotide and the mTOR Inhibitor RAD001 (Everolimus) Block Proliferation and Interact with the Akt-mTOR-p70S6K Pathway in a Neuro-Endocrine Tumour Cell Line
- (2007) Simona Grozinsky-Glasberg et al. NEUROENDOCRINOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More